Pacer Advisors
KROS icon

Pacer Advisors’s Keros Therapeutics KROS Stock Holding History

Pacer Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-327
Closed -$14.9K – 2629
2024
Q2 		$14.9K Sell
327
-233
-42% -$12.5K ﹤0.01% 3484
2024
Q1 		$37.1K Buy
+560
New +$33.2K ﹤0.01% 3293
2021
Q2 		– Sell
-790
Closed -$49K – 1484
2021
Q1 		$49K Buy
790
+358
+83% +$22.7K ﹤0.01% 1439
2020
Q4 		$30K Buy
+432
New +$27.2K ﹤0.01% 1462

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Pacer Advisors's KROS Position: Q3 2024 in Review

Pacer Advisors sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 327 shares — an estimated $14.9K sold.

Pacer Advisors first reported a position in KROS in Q4 2020 and held it in 4 quarters. The position peaked at $49K in Q1 2021. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

  • Pacer Advisors reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 327 Keros Therapeutics shares in Q3 2024, an estimated $14.9K.
  • Pacer Advisors first reported a position in Keros Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Keros Therapeutics position peaked at $49K in Q1 2021.
  • 163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.